Bio-Rad Q2 revenue flat at $651M; announces restructuring plan with $80-90M charges

BIO-RAD LABORATORIES, INC.

Q2 net sales $651.0M flat YoY; GAAP diluted EPS $13.85, non-GAAP diluted EPS $2.62.
Clinical Diagnostics grew; Life Science soft but digital PCR revenue up >20%.
Restructuring plan initiated July 31, 2026; pre-tax charges estimated $80-90M, primarily severance and facility closures.
Plan expected substantially complete by end of FY2027; includes position eliminations and function consolidation.
Generated $98.7M operating cash flow; repurchased ~$32M shares; full-year outlook reaffirmed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.